We analyzed the disease-specific outcomes of adult patients with advanced myelodysplastic syndrome (MDS) treated with cord blood transplantation (CBT) after myeloablative conditioning. Between August 1998 and June 2009, 33 adult patients with advanced MDS were treated with unrelated CBT. The diagnoses at transplantation included refractory anemia with excess blasts (n ¼ 7) and MDS-related secondary AML (sAML) (n ¼ 26). All patients received four fractionated 12 Gy TBI and chemotherapy as myeloablative conditioning. The median age was 42 years, the median weight was 55 kg and the median number of cryopreserved nucleated cells was 2.51 Â 10 7 cells per kg. The cumulative incidence of neutrophil recovery at day 50 was 91%. Neutrophil recovery was significantly faster in sAML patients (P ¼ 0.04). The cumulative incidence of plt recovery at day 200 was 88%. Plt recovery was significantly faster in CMV seronegative patients (Po0.001). The cumulative incidence of grade II-IV acute GVHD (aGVHD) and extensive-type chronic GVHD was 67 and 34%, respectively. Degree of HLA mismatch had a significant impact on the incidence of grade II-IV aGVHD (P ¼ 0.021). TRM and relapse at 5-years was 14 and 16%, respectively. The probability of EFS at 5 years was 70%. No factor was associated with TRM, relapse and EFS. These results suggest that adult advanced MDS patients without suitable related or unrelated BM donors should be considered as candidates for CBT.
Introduction
The prognosis of advanced myelodysplastic syndrome (MDS) is poor. Although some patients with advanced MDS achieve remission with standard intensive chemotherapy, the duration is usually limited.
1 Therefore, Allo-SCT is considered as the only curative therapy for MDS patients. Alternative donor sources other than HLA-identical siblings have been used as allogeneic stem cell sources.
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Recently, umbilical cord blood from unrelated donors has been used as an alternative stem cell source for adult patients. [7] [8] [9] [10] [11] [12] [13] [14] [15] However, reports of disease-specific outcomes for adult patients with advanced MDS after cord blood transplantation (CBT) are still limited. We have previously reported the results of a group of 19 adult patients with advanced MDS who received unrelated CBT. 16, 17 Here, we have updated the results of unrelated CBT after myeloablative conditioning for 33 adult patients with advanced MDS. The main purpose of this retrospective single-center study was to confirm the safety and efficacy of unrelated CBT for adult advanced MDS patients after a myeloablative conditioning regimen, as well as to identify pretransplant factors related to the transplant outcomes on long-term follow-up.
Patients and methods

Patients
This was a retrospective single-center analysis. Between August 1998 and June 2009, 33 adult patients with advanced MDS were treated with unrelated CBT at The Institute of Medical Science, University of Tokyo. The diagnosis of MDS was made for all patients according to the World Health Organization classification. The diagnosis at transplantation included refractory anemia with excess blasts (1/2) (n ¼ 7) and MDS-related secondary AML (sAML) (n ¼ 26). MDS-related sAML was defined as AML that developed during the follow-up period of MDS. The cytogenetic subgroups according to a transplantationspecific cytogenetics grouping for MDS 18 were adverse risk (abnormalities of chromosome 7 and complex karyotype) in 10 patients and standard risk (all others) in 23 patients. Written informed consent for treatment was obtained from all patients.
Cord blood unit selection
The HLA-A and HLA-B Ags were identified by serological typing. HLA-DRB1 alleles were determined by highresolution molecular typing using PCR sequence-specific primers. Patients without a suitable, closely HLA-matched family donor were eligible for CBT if a matched unrelated BM donor was unavailable as a first treatment option. If there was insufficient time for an unrelated BM donor search because of disease status or because preliminary search indicated a low likelihood of obtaining a matched unrelated BM donor, we attempted to locate cord blood grafts. Preferred cord blood units matched three or more of six HLA loci and contained a minimal cell count of 1.5 Â 10 7 nucleated cells per kg before freezing. All but one cord blood units were obtained from cord blood banks in the Japan Cord Blood Bank Network.
Conditioning
All patients received four fractionated 12 Gy TBIs on days À9, À8 or on days À8 and À7, recombinant human G-CSF combined Ara-C and CY. Ara-C was administered i.v. over 2 h at a dose of 3 g/m 2 every 12 h on days À6 and À5 or on days À5 and À4 (total dose, 12 g/m 2 ). G-CSF was administered by continuous infusion at a dose of 5 mg/kg per day. Infusion of G-CSF was started 12 h before the first dose of Ara-C and stopped at the completion of the last dose. CY was administered i.v. over 2 h at a dose of 60 mg/kg once daily on days À4 and À3 or on days À3 and À2 (total dose, 120 mg/kg). At 2 or 3 days after the completion of conditioning, patients received a CBT.
GVHD prophylaxis
All patients received standard CYA and MTX as GVHD prophylaxis. CYA was given i.v. every day starting on day À1 at a dose of 3 mg/kg per day. MTX (15 mg/m 2 i.v.) was given on day 1, and 10 mg/m 2 of MTX was administered on days 3 and 6. Once oral intake could be tolerated, patients were administered oral CYA at a dose of 1:2, in two divided doses per day, on the basis of the last i.v. dose. In the absence of GVHD, CYA was tapered beginning between weeks 6 and 9 until it could be discontinued in the absence of chronic GVHD (cGVHD) between 6 and 12 months after transplantation. CYA was reduced when serum creatinine levels rose 1.5 times above baseline or when other serious agent-associated toxicities occurred. Physicians could freely modify the CYA dose for patients experiencing severe acute GVHD (aGVHD) or risk of disease relapse. Corticosteroid-based treatment was considered when grade II or higher severe aGVHD occurred (0.5-2 mg/kg).
Supportive care
All patients received G-CSF by i.v. infusion starting on day 1 until durable granulocyte recovery was achieved. The supportive care regimen, including prophylaxis for infection, was the same as previously reported. 13 End points and definitions Myeloid engraftment was defined as the first of the 3 consecutive days during which the ANC was at least 0.5 Â 10 9 cells per l. Plt recovery time was achieved on the first of 3 days when the plt count was higher than 5 Â 10 9 cells per l without transfusion support. The chimerism status after CBT was determined either by FISH with a Y chromosome probe for sex-mismatched CBT or by quantitative PCR analysis for microsatellite DNA markers. Primary engraftment failure was defined as the absence of donor-derived myeloid cells on the day of death, the day of relapse and on day 60 in patients surviving after CBT. A second allogeneic transplantation or autologous hematopoietic reconstitution before donor-derived myeloid recovery was considered as primary engraftment failure. Both aGVHD and cGVHD were graded according to the previously published criteria. 19, 20 TRM was defined as death from any cause except relapse. Relapse was defined by morphological evidence of disease in peripheral blood, BM or extramedullary sites. EFS was defined as the time from CBT to graft failure, relapse, death or the last observation.
Statistical analysis
Cumulative incidences were estimated for hematopoietic recovery, GVHD, TRM and relapse to take competing risks into account. The probability of EFS was estimated from the time of CBT according to the Kaplan-Meier method. Variables considered in univariate analysis were body weight, age, recipient sex, degree of HLA matching, recipient CMV serology, diagnosis (MDS-related sAML or others), cytogenetic subgroups, year of transplant, total nucleated cell dose and CD34-positive cell dose. Variables with a value of Po0.1 for each end point were tested in multivariate analysis. End points were calculated at the last contact, the date of the last follow-up being 1 December 2009.
Results
Characteristics of patients and cord blood units
The characteristics of 33 patients and cord blood units are shown in Table 1 . Among the patients, the median age was 42 years (range, 19-52 years), the median weight was 55 kg (range, 41-75 kg), the median number of cryopreserved nucleated cells was 2.51 Â 10 7 cells per kg (range, 1.71-4.60 Â 10 7 cells per kg), and the median number of cryopreserved CD34-positive cells was 0.91 Â 10 5 cells per kg (range, 0.27-2.14 Â 10 5 cells per kg). All patients received a single and HLA-mismatched cord blood unit.
Hematopoietic recovery
A total of 30 patients had myeloid reconstitution, and the median time to achieve more than 0.5 Â 10 9 cells per l ANC was 22 days (range, 18-35 days). Three patients experienced primary engraftment failure. Of the three patients, one relapsed at day 53 and two died at days 24 and 28 without myeloid engraftment. The cumulative incidence of neutrophil recovery at day 50 was 91% (95% confidence interval (CI), 79.7-100%). In multivariate analysis, neutrophil recovery was significantly faster for sAML patients (P ¼ 0.04) ( Table 2) . A self-sustained plt count of more than 50 Â 10 9 cells per l was achieved in 29 patients at a median time of 51 days (range, 30-179 days). The cumulative incidence of plt recovery at day 200 was 88% (95% CI, 75.1-100%). In multivariate analysis, plt recovery was significantly faster for CMV seronegative patients (Po0.001) ( Table 2) . aGVHD and cGVHD Acute GVHD occurred in 28 of 30 evaluable patients. The grading of aGVHD was grade I in 12 patients, grade II in 10, grade III in 4 and grade IV in 2. The cumulative incidence of grade II-IV and grade III and IV aGVHD at day 100 after CBT was 67% (95% CI, 34.0-90.8%) and 41% (95% CI, 5.5-75.5%), respectively. In multivariate analysis, degree of HLA mismatch had a significant impact on the incidence of grade II-IV aGVHD (P ¼ 0.021) ( Table 2 ). cGVHD occurred in 25 of 28 evaluable patients. Among 25 cGVHD patients, 11 patients were of the extensive type. The cumulative incidence of overall and extensive-type cGVHD was 76% (95% CI, 60.4-91.2%) and 34% (95% CI, 17.4-51.2%), respectively. No factor was associated with the incidence of overall and extensivetype cGVHD.
Relapse
The cumulative incidence of relapse at 5 years was 16% (95% CI, 2.7-29.1%). No factor was associated with the incidence of relapse.
TRM and causes of death
The cumulative incidence of TRM at day 100 and at 5 years was 6% (95% CI, 0-14.4%) and 14% (95% CI, 0.8-27.0%), respectively. No factor was associated with TRM. Eight patients died. Of the eight patients, four died of relapse. In the remaining four patients, the causes of death were treatment related (organ failure (n ¼ 1), infection (n ¼ 1), cGVHD with or without infection (n ¼ 2)).
EFS
Of 33 patients, 24 are alive and event-free after CBT. Median follow-up of event-free survivors was 59 months (range, 5-137 months). The probability of EFS at 5 years was 70% (95% CI, 55.3-88.9%) (Figure 1) . No factor was associated with EFS.
Discussion
Several studies have suggested the promising results of unrelated CBT after myeloablative conditioning for adult patients. [7] [8] [9] [10] [11] [12] [13] [14] [15] Recently, reports of disease-specific outcomes for adult patients with acute leukemia after CBT have been published; [21] [22] [23] [24] however, there have been no reports detailing the long-term follow-up results of disease-specific outcomes of adult advanced MDS patients treated with CBT after myeloablative conditioning. Although we have previously reported the results of 19 adult patients with advanced MDS who received CBT after myeloablative conditioning, 16 ,17 the follow-up duration after CBT was Median time from diagnosis to transplantation, months (range) 9 (2-223)
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TBI+Ara-C/G-CSF+CY, n 33 short and risk factors associated with transplant outcomes were not analyzed. In addition, our recent report of the results of 77 adult patients with AML who received CBT included 20 patients with sAML; 21 however, the details of sAML-specific outcomes were not fully analyzed. Therefore, we updated the results of unrelated CBT after myeloablative conditioning for 33 adult patients with advanced MDS and identified pretransplant factors related to the transplant outcomes on long-term follow-up.
GVHD prophylaxis
In this study, the cumulative incidence of neutrophil recovery at day 50 was 91% and the median time to neutrophil recovery was 22 days. Of 33 patients, only 3 patients experienced primary engraftment failure. The diagnosis of sAML was identified as a significant factor affecting faster neutrophil recovery. One reason may be that two of the three patients who experienced primary engraftment failure had refractory anemia with excess blasts (2 of 7 refractory anemia with excess blasts patients experienced primary engraftment failure). The cumulative incidence of plt recovery at day 200 was 88%, and plt recovery was significantly faster for CMV seronegative patients. This finding is consistent with our previous report. 25 The cumulative incidence of grade II-IV aGVHD, grade III and IV aGVHD, overall and extensive-type cGVHD was 67, 41, 76 and 34%, respectively. As described before, 13 because immunosuppressants for CBT recipients tended to be discontinued faster in our institution, the incidence of aGVHD and cGVHD was relatively higher than other reports of adult CBT. However, the cumulative incidence of TRM at day 100 and at 5 years was very low (6 and 14%, respectively), and aGVHD and cGVHD were not related to TRM. In multivariate analysis, degree of HLA mismatch had a significant impact on the incidence of grade II-IV aGVHD. Recently, Arcese et al.
14 reported the updated results of a large series of adult patients with different hematopoietic malignancies transplanted in 63 centers of the Eurocord group. In total, 171 adult patients received CBT after myeloablative conditioning. They analyzed outcomes and risk factors after CBT. The cumulative incidence of grade II-IV aGVHD was 32%, and no factor was found to significantly influence the development or severity of aGVHD in multivariate analysis. Our previous studies 21, 22 and those of others, 7, 24 as well as that of Arcese et al. 14 reported that HLA matching had no effect on aGVHD after CBT in adults; however, the degree of HLA mismatch had a significant impact on aGVHD in this study. The reasons for this finding remain unclear because of the limited number of patients. The cumulative incidence of relapse at 5 years was 16% and the probability of EFS at 5 years was 70%. No factor was associated with relapse and EFS. Recently, a transplantation-specific cytogenetics grouping scheme for patients with MDS has been reported. 18 Under this scheme, abnormalities of chromosome 7 and complex karyotype are considered to be adverse risks, whereas all others are considered standard risk. Although, we performed univariate and multivariate analyses according to this transplantationspecific grouping, cytogenetics had no impact on the incidence of relapse and EFS. In this analysis, unrelated CBT after myeloablative conditioning can cure B70% of the adult patients with advanced MDS. As previously described, 13 ,15,21 a lower TRM rate and the use of G-CSFcombined preparative regimen, 21 which was capable of reducing the post transplant relapse rate in refractory myeloid malignancies, may be associated with encouraging outcomes in this study. In addition, Japanese patients might have some advantages in the setting of HLAmismatched transplantation because of HLA or non-HLA immune genetics.
In summary, we updated the results of unrelated CBT for adult advanced MDS patients. These results suggest that unrelated CBT after myeloablative conditioning could be safely and effectively used for adult patients with advanced MDS without suitable related or unrelated BM donors.
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